연구동향 분석
박사

Nomogram for Prediction of Pathologic Complete Remission Using Morphometric Change and Biomarker Expression in Rectal Cancer After Preoperative Chemoradiotherapy : 직장암의 수술 전 화학방사선요법 후 형태계측 변화와 바이오마커 발현을 이용한 병리학적 완전관해 예측 노모그램

Hur, Hyuk 2016년

논문상세정보
인용/피인용
' Nomogram for Prediction of Pathologic Complete Remission Using Morphometric Change and Biomarker Expression in Rectal Cancer After Preoperative Chemoradiotherapy : 직장암의 수술 전 화학방사선요법 후 형태계측 변화와 바이오마커 발현을 이용한 병리학적 완전관해 예측 노모그램' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • bio-marker
  • chemoradiotherapy
  • endoscopy
  • pathologic complete remission
  • prediction nomogram
  • rectal cancer
  • 내시경
  • 바이오마커
  • 병리학적 완전관해
  • 예측 노모그램
  • 직장암
  • 화학방사선요법
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,195 0

0.0%

' Nomogram for Prediction of Pathologic Complete Remission Using Morphometric Change and Biomarker Expression in Rectal Cancer After Preoperative Chemoradiotherapy : 직장암의 수술 전 화학방사선요법 후 형태계측 변화와 바이오마커 발현을 이용한 병리학적 완전관해 예측 노모그램' 의 참고문헌

  • Willett CG, Warland G, Hagan MP, et al. Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 1995;13:1417-24.
  • Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathology 2009;55:284-93.
  • Suzuki T, Sadahiro S, Tanaka A, et al. Biopsy specimens obtained 7 days after starting chemoradiotherapy (CRT) provide reliable predictors of response to CRT for rectal cancer. Int J Radiat Oncol Biol Phys 2013;85:1232- 8.
  • Spitz FR, Giacco GG, Hess K, et al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with highrisk rectal cancer. Clin Cancer Res 1997;3:1685-90.
  • Sim SH, Kang MH, Kim YJ, et al. P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. BMC Cancer 2014;14:241.
  • Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, Laurent- Puig P. Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 2002;100:131-5.
  • O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10.
  • Luna-Perez P, Segura J, Alvarado I, Labastida S, Santiago-Payan H, Quintero A. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol 2000;7:727-31.
  • Lin LC, Lee HH, Hwang WS, et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 2006;15:211-6.
  • Lassmann S, Bauer M, Soong R, et al. Quantification of CK20 gene and protein expression in colorectal cancer by RT-PCR and immunohistochemistry reveals inter- and intratumour heterogeneity. J Pathol 2002;198:198-206.
  • Kudrimoti M, Lee EY, Kang Y, Ahmed M, Mohiuddin M. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J Ky Med Assoc 2007;105:18-22.
  • Kikuchi M, Mikami T, Sato T, et al. High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for prediction. Br J Cancer 2009;101:116-23.
  • Kelley ST, Coppola D, Yeatman T, Marcet J. Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. Clin Colorectal Cancer 2005;5:114-8.
  • Kawamoto A, Tanaka K, Saigusa S, et al. Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. Exp Ther Med 2012;3:403-9.
  • Kandioler D, Zwrtek R, Ludwig C, et al. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 2002;235:493-8.
  • Hur H, Kim NK, Min BS, et al. Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer? Dis Colon Rectum 2014;57:592-601.
  • Huh JW, Lee JH, Kim HR. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer. Ann Surg 2014;259:508-15.
  • Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008;99:1285-9.
  • Habr-Gama A, Perez RO. Immediate surgery or clinical follow-up after a complete clinical response? Recent Results Cancer Res 2014;203:203- 10.
  • Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-5.
  • Diez M, Ramos P, Medrano MJ, et al. Preoperatively irradiated rectal carcinoma: analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining. Oncology 2003;64:213-9.
  • Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-64.
  • Chen Z, Duldulao MP, Li W, Lee W, Kim J, Garcia-Aguilar J. Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg 2011;212:1008- 17.e1.
  • Charara M, Edmonston TB, Burkholder S, et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 2004;24:3161-7.
  • Chang HJ, Jung KH, Kim DY, et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 2005;36:364-71.
  • Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006;93:1215-23.
  • Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ, Kay EW. GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer 2009;125:2778-82.
  • Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
  • Borg C, Andre T, Mantion G, et al. Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. Ann Oncol 2014;25:2205-10.
  • Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;68:1455-61.
  • Artells R, Moreno I, Diaz T, et al. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer 2010;46:642-9.